Autolus Therapeutics (AUTL) 6-K 5 May 22 Index to Condensed Consolidated Financial Statements Financial data

Cover

Cover	3 Months Ended
	Mar. 31, 2022
Cover [Abstract]
Entity Registrant Name	Autolus Therapeutics plc
Entity Central Index Key	0001730463
Document Type	6-K
Document Period End Date	Mar. 31, 2022
Amendment Flag	false
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q1
Current Fiscal Year End Date	--12-31

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash	$ 268,558	$ 310,338
Restricted cash	334	338
Prepaid expenses and other assets, current	40,571	36,276
Total current assets	309,463	346,952
Non-current assets:
Property and equipment, net	31,017	33,541
Prepaid expenses and other non-current assets	2,119	2,362
Operating lease right-of-use assets	17,366	18,775
Long-term deposits	1,983	2,039
Deferred tax asset	2,000	1,826
Intangible assets, net	46	65
Total assets	363,994	405,560
Current liabilities:
Accounts payable	153	431
Accrued expenses and other liabilities	24,513	23,667
Operating lease liabilities	4,174	4,453
Total current liabilities	28,840	28,551
Non-current liabilities:
Operating lease liabilities, net of current portion	15,081	16,545
Liability related to sale of future royalties and sales milestones, net	48,806	47,016
Other long-term payables	124	128
Total liabilities	92,851	92,240
Commitments and contingencies (Note 11)
Shareholders' equity:
Additional paid-in capital	845,448	843,108
Accumulated other comprehensive loss	(16,025)	(8,570)
Accumulated deficit	558,402	521,340
Total shareholders' equity	271,143	313,320
Total liabilities and shareholders' equity	363,994	405,560
Ordinary shares
Shareholders' equity:
Share value	4	4
Deferred shares
Shareholders' equity:
Share value	0	0
Deferred B Shares
Shareholders' equity:
Share value	118	118
Deferred C Shares
Shareholders' equity:
Share value	$ 0	$ 0

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)	Mar. 31, 2022$ / sharesshares	Mar. 31, 2022£ / sharesshares	Dec. 31, 2021$ / sharesshares	Dec. 31, 2021£ / sharesshares
Ordinary shares
Shareholders' equity:
Stock par value (usd/gbp per share) | $ / shares	$ 0.000042		$ 0.000042
Shares authorized	200,000,000	200,000,000	200,000,000	200,000,000
Shares issued	90,907,941	90,907,941	90,907,830	90,907,830
Shares outstanding	90,907,941	90,907,941	90,907,830	90,907,830
Deferred shares
Shareholders' equity:
Stock par value (usd/gbp per share) | £ / shares		£ 0.00001		£ 0.00001
Shares authorized	34,425	34,425	34,425	34,425
Shares issued	34,425	34,425	34,425	34,425
Shares outstanding	34,425	34,425	34,425	34,425
Deferred B Shares
Shareholders' equity:
Stock par value (usd/gbp per share) | £ / shares		£ 0.00099		£ 0.00099
Shares authorized	88,893,548	88,893,548	88,893,548	88,893,548
Shares issued	88,893,548	88,893,548	88,893,548	88,893,548
Shares outstanding	88,893,548	88,893,548	88,893,548	88,893,548
Deferred C Shares
Shareholders' equity:
Stock par value (usd/gbp per share) | £ / shares		£ 0.000008		£ 0.000008
Shares authorized	1	1	1	1
Shares issued	1	1	1	1
Shares outstanding	1	1	1	1

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Income Statement [Abstract]
Grant income	$ 166	$ 269
Operating expenses:
Research and development	(33,963)	(30,731)
General and administrative	(7,987)	(8,738)
Loss on disposal of leasehold improvements	0	(672)
Total operating expenses, net	(41,784)	(39,872)
Other income (expense):
Interest income	28	44
Other income, net	860	838
Interest expense	(1,790)	0
Total other (expense) income, net	(902)	882
Net loss before income tax	(42,686)	(38,990)
Income tax benefit	5,624	5,724
Net loss attributable to ordinary shareholders	(37,062)	(33,266)
Other comprehensive (loss) income:
Foreign currency exchange translation adjustment	(7,455)	1,273
Total comprehensive loss	$ (44,517)	$ (31,993)
Basic net loss per ordinary share (in usd per share)	$ (0.41)	$ (0.53)
Diluted net loss per ordinary share (in usd per share)	$ (0.41)	$ (0.53)
Weighted-average basic ordinary shares (in shares)	90,914,175	62,447,606
Weighted-average diluted ordinary shares (in shares)	90,914,175	62,447,606

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Shareholders’ Equity (Unaudited) - USD ($) $ in Thousands	Total	Common sharesOrdinary Shares	Common sharesDeferred Shares	Common sharesDeferred B Shares	Common sharesDeferred C Shares	Additional Paid in Capital	Accumulated other comprehensive loss	Accumulated deficit
Beginning balance at Dec. 31, 2020	$ 210,032	$ 3	$ 0	$ 118	$ 0	$ 595,016	$ (5,861)	$ (379,244)
Beginning balance (in shares) at Dec. 31, 2020		52,346,231	34,425	88,893,548	1
Stockholders' Equity
Issuance of ordinary shares, net of issuance costs	122,198					122,198
Issuance of ordinary shares, net of issuance costs (in shares)		18,147,078
Share-based compensation expense and reversal	(670)					(670)
Vesting of restricted stock (in shares)		21,500
Exercise of share options (in shares)		545
Unrealized loss on foreign currency translation	1,273						1,273
Net loss	(33,266)							(33,266)
Ending balance at Mar. 31, 2021	299,567	$ 3	$ 0	$ 118	$ 0	716,544	(4,588)	(412,510)
Ending balance (in shares) at Mar. 31, 2021		70,515,354	34,425	88,893,548	1
Beginning balance at Dec. 31, 2021	313,320	$ 4	$ 0	$ 118	$ 0	843,108	(8,570)	(521,340)
Beginning balance (in shares) at Dec. 31, 2021		90,907,830	34,425	88,893,548	1
Stockholders' Equity
Share-based compensation expense and reversal	2,340					2,340
Exercise of share options (in shares)		111
Unrealized loss on foreign currency translation	(7,455)						(7,455)
Net loss	(37,062)							(37,062)
Ending balance at Mar. 31, 2022	$ 271,143	$ 4	$ 0	$ 118	$ 0	$ 845,448	$ (16,025)	$ (558,402)
Ending balance (in shares) at Mar. 31, 2022		90,907,941	34,425	88,893,548	1

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) $ in Thousands	3 Months Ended
	Mar. 31, 2022USD ($)	Mar. 31, 2021USD ($)
Cash flows from operating activities:
Net loss	$ (37,062)	$ (33,266)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	2,067	1,662
Non-cash share-based compensation	2,340	(670)
Non-cash interest expense	1,790	0
Loss on termination of operating lease	0	11
Loss on disposal of fixed assets and intangible assets	0	672
Deferred income tax	(174)	(280)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(5,429)	(5,050)
Prepaid expenses and other non-current assets	180	163
Long-term deposits	0	811
Accounts payable	(272)	1,085
Operating lease right of use assets, net	904	(902)
Accrued expenses and other liabilities	1,890	(1,649)
Current and non-current operating lease liabilities	(1,264)	70
Net cash used in operating activities	(35,030)	(37,343)
Cash flows from investing activities:
Purchases of property and equipment	(771)	(1,900)
Net cash used in investing activities	(771)	(1,900)
Cash flows from financing activities:
Proceeds of issuance of ordinary shares	0	130,897
Payments of equity issuance costs	(1)	(7,573)
Net cash (used in) provided by financing activities	(1)	123,324
Effect of exchange rate changes on cash and restricted cash	(5,982)	1,632
Net increase (decrease) in cash and restricted cash	(41,784)	85,713
Cash and restricted cash, beginning of period	310,676	154,085
Cash and restricted cash, end of period	268,892	239,798
Supplemental non-cash flow information
Property and equipment purchases included in accounts payable and accrued expenses	593	569
Capitalized implementation costs included in accrued expenses	0	190
Issuance costs included in accounts payable and accrued expenses	16	1,124
Lease assets terminated	0	28,517
Reconciliation of cash and restricted cash reported within the condensed consolidated balance sheets:
Cash	268,558	239,012
Restricted cash	334	786
Total cash and restricted cash	$ 268,892	$ 239,798

Nature of the Business

Nature of the Business	3 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of the Business	Nature of the Business Autolus Therapeutics plc (the “Company”) is a biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer. Using its broad suite of proprietary and modular T cell programming technologies, the Company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and attack and kill these cells. The Company believes its programmed T cell therapies have the potential to be best-in-class and offer cancer patients substantial benefits over the existing standard of care, including the potential for cure in some patients. The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including precl inical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from its product sales. The Company has funded its operations primarily with proceeds from the sale of its equity securities and more recently, from strategic financing arrangements and collaborations. The Company has incurred recurring losses since its inception, including net losses of $37.1 million and $33.3 million for the three months ended March 31, 2022 and 2021, respectively. The Company had an accumulated deficit of $558.4 million and $521.3 million as of March 31, 2022 and December 31, 2021, respectively. The Company expects to continue to generate operating losses for the foreseeable future. As of the date these financial statements are issued, the Company expects that its cash on hand at March 31, 2022 of $268.6 million will be sufficient to fund the Company’s operations for at least twelve months from the issuance date of these unaudited condensed consolidated financial statements. The future viability of the Company beyond that point is dependent on its ability to raise additional capital to finance its operations. The Company’s inability to raise additional capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies. There can be no assurances, however, that the Company's current operating plans will be achieved or that the Company can obtain additional funding on terms acceptable to the Company, or at all. Blackstone Agreements On November 6, 2021, the Company concurrently entered into the following agreements with BXLS V - Autobahn L.P, ("Blackstone"): (i) Strategic Collaboration and Financing Agreement (the “Blackstone Collaboration Agreement"), (ii) Securities Purchase Agreement (the “Blackstone Securities Purchase Agreement”), (iii) Warrant Agreement (the “Blackstone Warrant”) and (iv) a Registration Rights Agreement (the “Blackstone Registration Rights Agreement”). The Blackstone Collaboration Agreement, the Blackstone Securities Purchase Agreement, the Blackstone Warrant and the Blackstone Registration Rights Agreement are collectively referred to as the "Blackstone Agreements". The Blackstone Agreements were entered into and in contemplation of one another and, accordingly, the Company assessed the accounting for the Blackstone Agreements in the aggregate. Blackstone Collaboration Agreement Pursuant to the Blackstone Collaboration Agreement, Blackstone agreed to pay the Company up to $150 million to support the continued development of the Company's CD19 CAR T cell investigational therapy product candidate, obecabtagene autoleucel (obe-cel), as well as next generation product therapies of obe-cel in B-cell malignancies. The first $50 million was paid by Blackstone as an upfront payment and the remainder (up to $100 million) will be payable to the Company upon the achievement of certain specified clinical, manufacturing and regulatory milestones (each such payment, a “Blackstone Development Payment” and collectively, the "Blackstone Development Payments"). For further details of the Blackstone Collaboration Agreement, see Note 9, “Liability related to future sale of royalties and sales milestones, net". Blackstone Securities Purchase Agreement Pursuant to the Blackstone Securities Purchase Agreement, the Company sold 17,985,611 American Depositary Shares, ("ADSs") representing 17,985,611 ordinary shares, at a private placement price of $5.56 per ADS to Blackstone resulting in gross proceeds of $100 million. The Company received aggregate net proceeds of $98.0 million, after deducting its costs and issuance expenses. On April 15, 2022, pursuant to the Blackstone Registration Rights Agreement, the Company filed a registration statement with the Securities and Exchange Commission (the “SEC”) for the purpose of registering the ordinary shares underlying the ADSs issued to Blackstone pursuant to the Blackstone Securities Purchase Agreement and the ordinary shares underlying the ADSs to be issued to Blackstone upon valid exercise of the Blackstone Warrant. Blackstone Warrant Agreement Pursuant to the Blackstone Warrant, the Company issued Blackstone a warrant to purchase up to 3,265,306 ADSs representing 3,265,306 of the Company's ordinary shares, at an exercise price of $7.35 per ADS. The Blackstone Warrant is exercisable in whole or in part until November 6, 2026. Impact of COVID-19 Pandemic While the Company has not experienced any significant financial impact to date, as a result of the ongoing coronavirus 2019 (“COVID-19”) pandemic, the overall disruption caused by the COVID-19 pandemic on global healthcare systems, and the other risks and uncertainties associated with the pandemic, could cause its business, financial condition, results of operations and growth prospects to be materially adversely affected. The Company implemented a COVID-19 surveillance testing program available to Company staff who work on-site at the Company’s U.K. facility to minimize the spread of COVID-19 pandemic within the Company. The Company continues to track COVID-19 developments in Europe and the United States closely for their potential impact on the Company’s clinical trial sites, contract research organizations, logistics and supply chain to ensure it can continue to maintain clinical trial conduct and data integrity. As the patients in the Company’s clinical trials are severely immune suppressed as a consequence of their underlying disease and the treatment they receive in the trials, the Company is also monitoring other transmissible infectious diseases, including influenza. The Company is not aware of any specific event or circumstance that has impacted on its operations in a manner which would require the Company to update its estimates, judgments or revise the carrying value of its assets or liabilities during the three months ended March 31, 2022. However, these estimates may change, as new events occur and additional information is obtained, relating to the COVID-19 pandemic or otherwise. Changes in estimates would be recognized in the unaudited condensed consolidated financial statements as soon as they become known.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited condensed consolidated financial statements include those of the Company and its wholly owned subsidiaries, Autolus Limited, Autolus Inc. and Autolus GmbH, and have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). All intercompany accounts and transactions have been eliminated upon consolidation. The significant accounting policies used in preparation of these unaudited condensed consolidated financial statements are consistent with those discussed in Note 2, “Summary of Significant Accounting Policies” in the Company’s Annual Report on Form 20-F for the year ended December 31, 2021 as filed with the Securities and Exchange Commission on March 10, 2022 (the “Annual Report”). In the opinion of management, all adjustments considered necessary to present fairly the results of the interim periods have been included and consist only of normal and recurring adjustments. Certain information and footnote disclosures have been condensed or omitted as permitted under U.S. GAAP. The results for the three months ended March 31, 2022 are not necessarily indicative of the results to be expected for the year ending December 31, 2022, any other interim periods, or any future year or period. As such, the information included in these unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the related notes thereto as of and for the year ended December 31, 2021, included in the Annual Report. Recent Accounting Pronouncements Not Yet Adopted

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	3 Months Ended
	Mar. 31, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid Expenses and Other Assets, Current	Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consisted of the following (in thousands): March 31, December 31, 2022 2021 Research and development claims receivable $ 28,508 $ 23,678 Prepayments 7,770 8,713 VAT receivable 2,403 1,849 Lease and lease deposit receivable 54 68 Other asset 83 240 Grant income receivable 487 384 Other receivable 396 271 Deferred cost 870 1,073 Total prepaid expenses and other current assets $ 40,571 $ 36,276

Property and Equipment, Net

Property and Equipment, Net	3 Months Ended
	Mar. 31, 2022
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	Property and Equipment, Net Property and equipment, net consisted of the following (in thousands): March 31, December 31, 2022 2021 Lab equipment $ 33,267 $ 34,091 Office equipment 3,376 3,463 Furniture and fixtures 1,326 1,363 Leasehold improvements 14,500 14,904 Assets under construction 2,632 2,436 Less: accumulated depreciation and impairment (24,084) (22,716) Total property and equipment, net $ 31,017 $ 33,541 Depreciation expense for the three months ended March 31, 2022 and 2021 wa s $2.0 million and $1.8 million, respectively.

Accrued Expenses and Other Liab

Accrued Expenses and Other Liabilities	3 Months Ended
	Mar. 31, 2022
Payables and Accruals [Abstract]
Accrued Expenses and Other Liabilities	Accrued Expenses and Other Liabilities Accrued expenses and other liabilities consisted of the following (in thousands): March 31, December 31, 2022 2021 Compensation and benefits $ 7,517 $ 8,747 Research and development costs 13,712 11,311 Professional fees 3,008 3,449 Other liabilities 277 160 Total accrued expenses and other liabilities $ 24,513 $ 23,667

Shareholders_ Equity

Shareholders’ Equity	3 Months Ended
	Mar. 31, 2022
Equity [Abstract]
Shareholders’ Equity	Shareholders’ Equity Ordinary Shares The Company is a public limited company incorporated in England and Wales. On June 22, 2018, the Company completed its initial public offering ("IPO") of ordinary shares in the form of ADSs. Each holder of ordinary shares is entitled to one vote per ordinary share and to receive dividends when and if such dividends are recommended by the Company's board of directors and declared by the shareholders. As of March 31, 2022, the Company has not declared any dividends. On February 12, 2021, the Company completed an underwritten public offering of 14,285,715 ADSs, which included the full exercise by the underwriters to purchase an additional 2,142,857 ADSs, at a public offering price of $7.00 per ADS. Aggregate net proceeds to the Company, after deducting underwriting discounts and offering expenses, were $106.9 million. In November 2021, pursuant to the Blackstone Securities Purchase Agreement, the Company sold 17,985,611 ADSs representing 17,985,611 ordinary shares, in a private placement price at a price of $5.56 per ADS to Blackstone resulting in gross proceeds of $100 million. The Company received aggregate net proceeds of $98.0 million, after deducting issuance expenses. As of March 31, 2022 the Company’s issued and outstanding share capital consi sted of (i) 90,907,941 o rdinary shares, with a nominal value of $0.000042 per share, (ii) 34,425 deferred shares, with a nominal value of £0.00001 per share, (iii) 88,893,548 B deferred shares, with a nominal value of £0.00099 per share and (iv) 1 C deferred share, with a nominal value of £0.000008. Each issued share has been fully paid. As at March 31, 2022, 62,040 ordinary shares underlying restrictive stock unit awards have vested however, these restricted stock unit awards have not been issued and, as such are not included in the Company's outstanding shares at March 31, 2022. Open Market Sale Agreement In September 2020, the Company entered into a Sale Agreement ("Sales Agreement") with Jefferies LLC (Jefferies), under which the Company may, at its option, offer and sell ADSs having an aggregate offering price of up to $100 million from time to time through Jefferies, acting as sales agent. Any such sales made through Jefferies can be made by any method that is deemed an “at-the-market offering” as defined in Rule 415 promulgated under the Securities Act of 1933, as amended (the “Securities Act”), or in other transactions pursuant to an effective shelf registration statement on Form F-3. The Company agreed to pay Jefferies a commission of 3.0% of the gross proceeds of any sales of ADSs sold pursuant to the Sales Agreement. During the three months ended March 31, 2022, the Company did not issue any ADSs under the Sales Agreement. During the year ended December 31, 2021, the Company issued an aggregate of 3,787,972 ADSs under the Sales Agreement for net proceeds, after deducting underwriting discounts and offering expenses of $29.6 million . As of March 31, 2022, $69.1 million worth of ADSs remained available for sale under the “at the market” equity offering program.

Share-based Compensation

Share-based Compensation	3 Months Ended
	Mar. 31, 2022
Share-based Payment Arrangement [Abstract]
Share-based Compensation	Share-based Compensation As at March 31, 2022, 62,040 ordinary shares underlying restricted stock unit awards have vested; however, the shares underlying these restricted stock unit awards have not been issued and, as such, are not included in the Company's outstanding shares at March 31, 2022. Share-based Compensation Expense Share-based compensation expense recorded as research and development expenses, general and administrative expenses is as follows (in thousands): Three Months Ended March 31, 2022 2021 Research and development $ 1,384 $ (1,654) General and administrative 956 984 Total share-based compensation $ 2,340 $ (670)

Net loss per share

Net loss per share	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Net loss per share	Net loss per share Basic and diluted net loss per share attributable to ordinary shareholders was calculated as follows (in thousands, except share and per share amounts): Three Months Ended March 31, 2022 2021 Numerator Net loss $ (37,062) $ (33,266) Net loss attributable to ordinary shareholders - basic and diluted $ (37,062) $ (33,266) Denominator Weighted-average number of ordinary shares used in net loss per share - basis and diluted 90,914,175 62,447,606 Net loss per share - basic and diluted $ (0.41) $ (0.53) For all periods presented, outstanding but unvested restricted shares and share options have been excluded from the calculation, because their effects would be anti-dilutive. Therefore, the weighted average shares outstanding used to calculate both basic and diluted loss per share are the same for all periods presented. The following potentially dilutive securities have been excluded from the calculation of diluted net loss per share due to their anti-dilutive effect: Three Months Ended March 31, 2022 2021 Unvested restricted incentive shares and units 1,023,810 1,360,159 Share options 8,407,272 6,881,620 Warrants 3,265,306 — Total 12,696,388 8,241,779

Liability related to sales of f

Liability related to sales of future royalties and sales milestones, net	3 Months Ended
	Mar. 31, 2022
Investments, Debt and Equity Securities [Abstract]
Liability related to sales of future royalties and sales milestones, net	Liability related to sales of future royalties and sales milestones, net The carrying amount of the Blackstone Collaboration Agreement liability is based on the Company’s estimate of the future royalties and sale milestones to be paid to Blackstone over the life of the Blackstone Collaboration Agreement as discounted using an effective interest rate. The excess of future estimated royalty and sale milestone payments over the initial $45.9 million of allocated consideration, less issuance costs, is recognized as non-cash interest expense using the effective interest method. The imputed rate of interest on the unamortized portion of the Blackstone Collaboration Agreement liability was approximately 15.80% as of March 31, 2022. On a quarterly basis, the Company will assess the amount and timing of expected royalty and sale milestone payments using a combination of internal projections and forecasts from external sources. To the extent such payments are greater or less than its initial estimates or the timing of such payments is materially different than its original estimates, the Company will adjust the amortization of the Blackstone Collaboration Agreement liability and the effective interest rate using the catch-up method. There are a number of factors that could materially affect the amount and timing of royalty and milestone payments, most of which are not within the Company’s control. The Blackstone Collaboration Agreement liability is recognized using significant unobservable inputs. These inputs are derived using internal management estimates developed based on third party data and reflect management’s judgements, current market conditions surrounding competing products, and forecasts. The significant unobservable inputs include the estimated patient population, estimated selling price, estimated peak sales and sales ramp, the expected term of the royalty stream, timing of the expected launch and its impact on the royalty rate as well as the overall probability of a success. A significant change in unobservable inputs could result in a material increase or decrease to the effective interest rate of the Blackstone Collaboration Agreement liability. The following table shows the activity within the liability related to the sale of future royalties and sales milestones for the three month period ended March 31, 2022 (in thousands): March 31, 2022 Balance as of December 31, 2021 $ 47,016 Non-cash interest expense on liability related to sale of future royalties and sales milestones 1,790 Balance as of March 31, 2022 $ 48,806

Leases

Leases	3 Months Ended
	Mar. 31, 2022
Leases [Abstract]
Leases	Leases The Company leases certain office space, laboratory space, and equipment. At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Operating Leases In September 2017, the Company executed an arrangement with Catapult Limited to lease a manufacturing suite at the Cell and Gene Therapy Catapult manufacturing center in Stevenage, United Kingdom for a term through May 2021, at which time the Company had the option to renew or terminate the lease. The lease had a six-month rent-free period. In December 2018, the Company executed an additional lease arrangement for additional manufacturing space for a term through September 2023, at which time the Company has the option to renew or terminate the lease. In October 2018, the Company executed an agreement to sublease office space in Rockville, Maryland for a term through October 2021. The Company then terminated the sublease in February 2020 and immediately entered into a five-year lease for the same space with the landlord. The lease related to this facility is classified as an operating lease. In January 2019, the Company executed a lease agreement with Whitewood Media Village GP Limited and Whitewood Media Village Nominee Limited to lease the fifth floor of MediaWorks including laboratory space. The Company has the option to terminate the lease in November 2026. In August 2021, MediaWorks became the Company's main corporate headquarters. The lease term is nine years and eleven months with an eighteen-month rent free period at the beginning of the lease term. In January 2019, the Company executed a lease agreement to lease additional office and manufacturing space in Rockville, Maryland. The lease agreement required the Company to enter into a lease provided that the landlord completed the required leasehold improvements described in the agreement. The lease commenced in August 2020 for a term through June 2036. In March 2021, the Company announced plans to move the site of its global manufacturing headquarters to the United Kingdom from the United States. As a part of this strategy, the Company entered into a termination agreement with the landlord of its Rockville, Maryland property to terminate the lease for office and manufacturing space. In February 2019 the Company entered into a fifteen-year lease for three manufacturing units in Enfield, United Kingdom with option to terminate the lease in February 2029. In addition to base rent, the Company is obligated to pay its proportionate share of building operating expenses and real estate taxes in excess of base year amounts. In March 2021, the Company surrendered one of the units. Upon the surrender, the Company recognized a $0.1 million gain in other (expense) income after recognizing a termination fee of $0.2 million. The Company has no further obligations for the surrendered unit and the right of use asset and lease liability which were recorded for this unit have been written off in the period. The Company subleased two of the three units to two third parties with lease terms ranging from October, 2021 to February 2029 and October 2026, respectively. The Company is actively seeking to sublease or assign the lease arrangements relating to the final unit to a third party. The Company completed an asset impairment analysis of the right-of-use lease concluding the undiscounted cash flows exceeded the carrying value as of March 31, 2022. In May 2020, the Company executed an arrangement with Catapult Limited to lease a manufacturing suite at the Cell and Gene Therapy Catapult manufacturing center in Stevenage, United Kingdom for a term through April 2024. The following table contains a summary of the lease costs recognized under ASU 2016-02 and other information pertaining to the Company’s operating leases for the three months ended March 31, 2022 and 2021 (in thousands): Three Months Ended March 31, Lease costs Statement of Operations Classification 2022 2021 Operating lease costs Operating expenses: research and development $ 987 $ 1,572 Variable costs Operating expenses: research and development 119 317 Short term lease costs Operating expenses: research and development 27 41 Operating lease costs Operating expenses: general and administrative 272 60 Variable costs Operating expenses: general and administrative 15 250 Short term lease costs Operating expenses: general and administrative 10 14 Total lease costs $ 1,430 $ 2,254 Three Months Ended March 31, Other information 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash outflows from operating leases (in thousands) $ 1,619 $ 1,034 Right-of-use assets obtained in exchange for new operating lease liabilities (in thousands) $ — $ (39,081) Weighted-average remaining lease term - operating leases (in years) 5.50 years 5.80 years Weighted-average discount rate - operating leases 7.15 % 6.70 % Future fixed payments for non-cancellable operating leases in effect as of March 31, 2022 are payable as follows: (in thousands): 2022 $ 4,050 2023 4,804 2024 4,141 2025 2,903 2026 2,671 Thereafter 4,647 Total lease payments $ 23,216 Less: imputed interest $ (3,961) Present value of lease liabilities $ 19,255 Sublease Agreements In October 2021, the Company entered into two separate sublease agreements with third parties for two manufacturing units in Enfield, United Kingdom which are currently leased by the Company. The annual lease payments to be received for each of subleased units is $97,000 and $109,000, over lease terms from October 2021 to February 2029 and October 2026, respectively. The Company received $127,000 in rental deposits, arising from the sublease agreements which have been classified as restricted cash as of March 31, 2022. Both subleases have been classified as operating leases. The Company recognize sublease payments on a straight-line basis from the commencement of the sublease agreements. The following table shows the sublease rental income for the three months ended March 31, 2022 and 2021 (in thousands): Three Months Ended March 31, Sublease rental income Statement of Operations Classification 2022 2021 Sublease rental income Other income, net 65 — Total sublease rental income $ 65 $ — Future fixed receipts for non-cancellable operating subleases in effect as of March 31, 2022 are receivable as follows (in thousands): 2022 $ 203 2023 270 2024 270 2025 270 2026 211 Thereafter 237 Total lease payments receivable $ 1,461

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies License Agreements The Company has entered into an exclusive license agreement with UCL Business Ltd, ("UCLB") which has subsequently been amended and restated. In connection with the UCLB license agreement, the Company is required to make annual license payments and may be required to make payments to UCLB upon the achievement of specified milestones. In November 2019, the Company entered into an exclusive license agreement with Noile-Immune Biotech Inc. ("Noile") under which the Company will have the right to develop CAR T cell therapies incorporating Noile’s PRIME (proliferation-inducing and migration-enhancing) technology. The Company may be obligated to make additional payments to Noile upon the achievement of development milestones and receipt of regulatory approvals product sale milestones, as well as royalty payments based on possible future sales resulting from the utilization of the licensed technology. The Company has estimated the probability of the Company achieving each potential milestone in relation to the UCLB and Niole License Agreements in accordance with ASC 450, Contingencies . The Company concluded that, as of March 31, 2022, there were no milestones for which the likelihood of achievement was currently probable. Legal Proceedings From time to time, the Company may be a party to litigation or subject to claims incident to the ordinary course of business. Regardless of the outcome, litigation can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources and other factors. The Company was not a party to any litigation and did not have contingency reserves established for any liabilities as of March 31, 2022 and December 31, 2021. Blackstone Strategic Collaboration and Financing Agreement Refer to Note 9, "Liability related to sales of future royalties and sales milestone, net" for further details to the Blackstone Collaboration Agreement . Leases Lease payments under operating leases as of March 31, 2022 and information about the Company’s lease arrangements are disclosed in Note 10, "Leases".

Employee Benefit Plans and Seve

Employee Benefit Plans and Severance Plan	3 Months Ended
	Mar. 31, 2022
Retirement Benefits [Abstract]
Employee Benefit Plans and Severance Plan	Employee Benefit Plans and Severance PlanDuring January 2021, there was a restructuring program executed by the Company leading to a reduction in workforce resulting in a corresponding severance charge of $1.2 million which has been presented on proportionate basis with research and development expenses and general and administration expenses.

Related parties

Related parties	3 Months Ended
	Mar. 31, 2022
Related Party Transactions [Abstract]
Related parties	Related parties Blackstone Agreements In November, 2021, the Company concurrently entered into the Blackstone Agreements. Subsequent to the execution of the Blackstone Agreements, Blackstone became a related party of the Company. Blackstone owns more than 10% of the Company's outstanding voting securities and is therefore one of the principal owners of the Company. In addition, Blackstone received the right to nominate one director to the board of directors of the Company. For further details of the Blackstone Collaboration Agreement, see Notes 1 and 9 for further details. As of March 31, 2022, the carrying amount of the Blackstone Collaboration Agreement liability was $48.8 million which included non-cash interest of $2.9 million. Refer to Note 9, " Liability related to sales of future royalties and sales milestone, net " for further details. Syncona Portfolio Limited Syncona Portfolio Limited is a related party of the Company as Syncona Portfolio Limited owns more than 10% of the Company's outstanding voting securities and is therefore one of the principal owners of the Company. In addition, the chief executive officer of the ultimate parent company of Syncona Portfolio Limited is also member of the board of directors of the Company.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2022
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events The Company evaluated subsequent events through May 5, 2022, the date on which these financial statements were is sued. The Company has concluded that no subsequent event has occurred that requires disclosure.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements include those of the Company and its wholly owned subsidiaries, Autolus Limited, Autolus Inc. and Autolus GmbH, and have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). All intercompany accounts and transactions have been eliminated upon consolidation. The significant accounting policies used in preparation of these unaudited condensed consolidated financial statements are consistent with those discussed in Note 2, “Summary of Significant Accounting Policies” in the Company’s Annual Report on Form 20-F for the year ended December 31, 2021 as filed with the Securities and Exchange Commission on March 10, 2022 (the “Annual Report”). In the opinion of management, all adjustments considered necessary to present fairly the results of the interim periods have been included and consist only of normal and recurring adjustments. Certain information and footnote disclosures have been condensed or omitted as permitted under U.S. GAAP. The results for the three months ended March 31, 2022 are not necessarily indicative of the results to be expected for the year ending December 31, 2022, any other interim periods, or any future year or period. As such, the information included in these unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the related notes thereto as of and for the year ended December 31, 2021, included in the Annual Report.
Recent Accounting Pronouncements Not Yet Adopted	Recent Accounting Pronouncements Not Yet AdoptedThere are no new accounting pronouncements that have been issued by the Financial Accounting Standards Board, "FASB", that are applicable to the Company.

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Tables)	3 Months Ended
	Mar. 31, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets consisted of the following (in thousands): March 31, December 31, 2022 2021 Research and development claims receivable $ 28,508 $ 23,678 Prepayments 7,770 8,713 VAT receivable 2,403 1,849 Lease and lease deposit receivable 54 68 Other asset 83 240 Grant income receivable 487 384 Other receivable 396 271 Deferred cost 870 1,073 Total prepaid expenses and other current assets $ 40,571 $ 36,276

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	3 Months Ended
	Mar. 31, 2022
Property, Plant and Equipment [Abstract]
Schedule of Depreciation	Property and equipment, net consisted of the following (in thousands): March 31, December 31, 2022 2021 Lab equipment $ 33,267 $ 34,091 Office equipment 3,376 3,463 Furniture and fixtures 1,326 1,363 Leasehold improvements 14,500 14,904 Assets under construction 2,632 2,436 Less: accumulated depreciation and impairment (24,084) (22,716) Total property and equipment, net $ 31,017 $ 33,541

Accrued Expenses and Other Li_2

Accrued Expenses and Other Liabilities (Tables)	3 Months Ended
	Mar. 31, 2022
Payables and Accruals [Abstract]
Schedule of Accrued Expenses and Other Liabilities	Accrued expenses and other liabilities consisted of the following (in thousands): March 31, December 31, 2022 2021 Compensation and benefits $ 7,517 $ 8,747 Research and development costs 13,712 11,311 Professional fees 3,008 3,449 Other liabilities 277 160 Total accrued expenses and other liabilities $ 24,513 $ 23,667

Share-based Compensation (Table

Share-based Compensation (Tables)	3 Months Ended
	Mar. 31, 2022
Share-based Payment Arrangement [Abstract]
Schedule of Share Based Compensation Expense	Share-based compensation expense recorded as research and development expenses, general and administrative expenses is as follows (in thousands): Three Months Ended March 31, 2022 2021 Research and development $ 1,384 $ (1,654) General and administrative 956 984 Total share-based compensation $ 2,340 $ (670)

Net loss per share (Tables)

Net loss per share (Tables)	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	Basic and diluted net loss per share attributable to ordinary shareholders was calculated as follows (in thousands, except share and per share amounts): Three Months Ended March 31, 2022 2021 Numerator Net loss $ (37,062) $ (33,266) Net loss attributable to ordinary shareholders - basic and diluted $ (37,062) $ (33,266) Denominator Weighted-average number of ordinary shares used in net loss per share - basis and diluted 90,914,175 62,447,606 Net loss per share - basic and diluted $ (0.41) $ (0.53)
Schedule of Anti-dilutive Securities	The following potentially dilutive securities have been excluded from the calculation of diluted net loss per share due to their anti-dilutive effect: Three Months Ended March 31, 2022 2021 Unvested restricted incentive shares and units 1,023,810 1,360,159 Share options 8,407,272 6,881,620 Warrants 3,265,306 — Total 12,696,388 8,241,779

Liability related to sales of_2

Liability related to sales of future royalties and sales milestones, net (Tables)	3 Months Ended
	Mar. 31, 2022
Investments, Debt and Equity Securities [Abstract]
Liability related to sale of Revenue	The following table shows the activity within the liability related to the sale of future royalties and sales milestones for the three month period ended March 31, 2022 (in thousands): March 31, 2022 Balance as of December 31, 2021 $ 47,016 Non-cash interest expense on liability related to sale of future royalties and sales milestones 1,790 Balance as of March 31, 2022 $ 48,806

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2022
Leases [Abstract]
Lease Cost	The following table contains a summary of the lease costs recognized under ASU 2016-02 and other information pertaining to the Company’s operating leases for the three months ended March 31, 2022 and 2021 (in thousands): Three Months Ended March 31, Lease costs Statement of Operations Classification 2022 2021 Operating lease costs Operating expenses: research and development $ 987 $ 1,572 Variable costs Operating expenses: research and development 119 317 Short term lease costs Operating expenses: research and development 27 41 Operating lease costs Operating expenses: general and administrative 272 60 Variable costs Operating expenses: general and administrative 15 250 Short term lease costs Operating expenses: general and administrative 10 14 Total lease costs $ 1,430 $ 2,254 Three Months Ended March 31, Other information 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash outflows from operating leases (in thousands) $ 1,619 $ 1,034 Right-of-use assets obtained in exchange for new operating lease liabilities (in thousands) $ — $ (39,081) Weighted-average remaining lease term - operating leases (in years) 5.50 years 5.80 years Weighted-average discount rate - operating leases 7.15 % 6.70 %
Lease Maturity Schedule	Future fixed payments for non-cancellable operating leases in effect as of March 31, 2022 are payable as follows: (in thousands): 2022 $ 4,050 2023 4,804 2024 4,141 2025 2,903 2026 2,671 Thereafter 4,647 Total lease payments $ 23,216 Less: imputed interest $ (3,961) Present value of lease liabilities $ 19,255
Sublease Classification	The following table shows the sublease rental income for the three months ended March 31, 2022 and 2021 (in thousands): Three Months Ended March 31, Sublease rental income Statement of Operations Classification 2022 2021 Sublease rental income Other income, net 65 — Total sublease rental income $ 65 $ —
Lease Receivable Maturity Schedule	Future fixed receipts for non-cancellable operating subleases in effect as of March 31, 2022 are receivable as follows (in thousands): 2022 $ 203 2023 270 2024 270 2025 270 2026 211 Thereafter 237 Total lease payments receivable $ 1,461

Nature of the Business - Narrat

Nature of the Business - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands	Nov. 06, 2021	Dec. 31, 2021	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Class of Stock
Net loss			$ (37,062)	$ (33,266)
Accumulated deficit		$ 521,340	558,402		$ 521,340
Cash		$ 310,338	268,558	$ 239,012	310,338
Proceeds of issuance of ordinary shares, net of issuance costs					$ 29,600
Exercise price of warrant	$ 7.35
American Depositary Shares Under Blackstone Agreement
Class of Stock
Class of warrant, number of securities called by warrants or rights	3,265,306
Blackstone
Class of Stock
Variable consideration amount at agreement inception			150,000
Blackstone | Affiliated Entity
Class of Stock
Contract with customer, liability gross			50,000
Variable consideration amount			$ 100,000
Ordinary Shares
Class of Stock
Number of shares issued in transaction		17,985,611			3,787,972
Per share price of issuance (usd per share)	$ 5.56
Sale of stock, consideration received	$ 100,000
Proceeds of issuance of ordinary shares, net of issuance costs	$ 98,000
Ordinary Shares | Ordinary Shares Represented by ADSs Under Blackstone Agreement
Class of Stock
Class of warrant, number of securities called by warrants or rights	3,265,306

Prepaid Expenses and Other Cu_3

Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Research and development claims receivable	$ 28,508	$ 23,678
Prepayments	7,770	8,713
VAT receivable	2,403	1,849
Lease and lease deposit receivable	54	68
Other asset	83	240
Grant income receivable	487	384
Other receivable	396	271
Deferred cost	870	1,073
Total prepaid expenses and other current assets	$ 40,571	$ 36,276

Property and Equipment, Net (De

Property and Equipment, Net (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment
Less: accumulated depreciation and impairment	$ (24,084)	$ (22,716)
Total property and equipment, net	31,017	33,541
Lab equipment
Property, Plant and Equipment
Property and equipment, gross	33,267	34,091
Office equipment
Property, Plant and Equipment
Property and equipment, gross	3,376	3,463
Furniture and fixtures
Property, Plant and Equipment
Property and equipment, gross	1,326	1,363
Leasehold improvements
Property, Plant and Equipment
Property and equipment, gross	14,500	14,904
Assets under construction
Property, Plant and Equipment
Property and equipment, gross	$ 2,632	$ 2,436

Property and Equipment, Net - N

Property and Equipment, Net - Narratives (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 2	$ 1.8

Accrued Expenses and Other Li_3

Accrued Expenses and Other Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Compensation and benefits	$ 7,517	$ 8,747
Research and development costs	13,712	11,311
Professional fees	3,008	3,449
Other liabilities	277	160
Total accrued expenses and other liabilities	$ 24,513	$ 23,667

Shareholders_ Equity - Narrativ

Shareholders’ Equity - Narrative (Details) $ / shares in Units, $ in Millions	Nov. 06, 2021USD ($)$ / shares	Feb. 12, 2021USD ($)$ / sharesshares	Dec. 31, 2021$ / sharesshares	Dec. 31, 2021USD ($)$ / sharesshares	Mar. 31, 2022£ / shares	Mar. 31, 2022USD ($)$ / sharesshares	Dec. 31, 2021£ / sharesshares	Sep. 18, 2020USD ($)
Class of Stock
Proceeds of issuance of ordinary shares, net of issuance costs | $				$ 29.6
Sale of stock, authorized amount | $								$ 100
Commission, percentage of gross sales price								0.030
Sale of stock, remaining authorized amount | $						$ 69.1
Unvested restricted incentive shares and units
Class of Stock
Vested not issued (in shares)						62,040
Ordinary shares
Class of Stock
Number of shares issued in transaction			17,985,611	3,787,972
Per share price of issuance (usd per share) | $ / shares	$ 5.56
Proceeds of issuance of ordinary shares, net of issuance costs | $	$ 98
Sale of stock, consideration received | $	$ 100
Shares issued			90,907,830	90,907,830		90,907,941	90,907,830
Shares outstanding			90,907,830	90,907,830		90,907,941	90,907,830
Stock par value (usd/gbp per share) | $ / shares			$ 0.000042	$ 0.000042		$ 0.000042
Ordinary shares | Underwriters public offering
Class of Stock
Number of shares issued in transaction		14,285,715
Per share price of issuance (usd per share) | $ / shares		$ 7
Proceeds of issuance of ordinary shares, net of issuance costs | $		$ 106.9
Ordinary shares | Options
Class of Stock
Number of shares issued in transaction		2,142,857
Deferred Shares
Class of Stock
Shares issued			34,425	34,425		34,425	34,425
Shares outstanding			34,425	34,425		34,425	34,425
Stock par value (usd/gbp per share) | £ / shares					£ 0.00001		£ 0.00001
Deferred B Shares
Class of Stock
Shares issued			88,893,548	88,893,548		88,893,548	88,893,548
Shares outstanding			88,893,548	88,893,548		88,893,548	88,893,548
Stock par value (usd/gbp per share) | £ / shares					0.00099		£ 0.00099
Deferred C Shares
Class of Stock
Shares issued			1	1		1	1
Shares outstanding			1	1		1	1
Stock par value (usd/gbp per share) | £ / shares					£ 0.000008		£ 0.000008

Share-based Compensation - Narr

Share-based Compensation - Narrative (Details)	Mar. 31, 2022shares
Unvested restricted incentive shares and units
Share-based Compensation Arrangement by Share-based Payment Award
Vested not issued (in shares)	62,040

Share-based Compensation - Shar

Share-based Compensation - Share-based Compensation Allocation (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award
Total share-based compensation	$ 2,340	$ (670)
Research and development
Share-based Compensation Arrangement by Share-based Payment Award
Total share-based compensation	1,384	(1,654)
General and administrative
Share-based Compensation Arrangement by Share-based Payment Award
Total share-based compensation	$ 956	$ 984

Net loss per share - Schedule o

Net loss per share - Schedule of Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Numerator
Net loss	$ (37,062)	$ (33,266)
Net loss attributable to ordinary shareholders - basic	(37,062)	(33,266)
Net loss attributable to ordinary shareholders - diluted	$ (37,062)	$ (33,266)
Denominator
Weighted-average number of ordinary shares used in net loss per share - basic (in shares)	90,914,175	62,447,606
Weighted-average number of ordinary shares used in net loss per share - diluted (in shares)	90,914,175	62,447,606
Earnings Per Share
Net loss per share - basic (in usd per share)	$ (0.41)	$ (0.53)
Net loss per share - diluted (in usd per share)	$ (0.41)	$ (0.53)

Net loss per share - Schedule_2

Net loss per share - Schedule of Anti-dilutive Securities (Details) - shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Antidilutive Securities
Anti-dilutive shares	12,696,388	8,241,779
Unvested restricted incentive shares and units
Antidilutive Securities
Anti-dilutive shares	1,023,810	1,360,159
Share options
Antidilutive Securities
Anti-dilutive shares	8,407,272	6,881,620
Warrants
Antidilutive Securities
Anti-dilutive shares	3,265,306	0

Liability related to sales of_3

Liability related to sales of future royalties and sales milestones, net - Narrative (Details) $ in Millions	3 Months Ended
	Mar. 31, 2022USD ($)
Class of Warrant or Right [Line Items]
Proceeds from royalties and sale milestones	$ 45.9
Strategic Collaboration and Financing Agreement
Class of Warrant or Right [Line Items]
Interest rate	15.80%

Liability related to sales of_4

Liability related to sales of future royalties and sales milestones, net - Schedule of Liability Related to Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Liability, Future Revenue, Rollforward [Abstract]
Balance as of December 31, 2021	$ 47,016
Non-cash interest expense on liability related to sale of future royalties and sales milestones	1,790	$ 0
Balance as of March 31, 2022	$ 48,806

Leases - Narrative (Details)

Leases - Narrative (Details) $ in Thousands	1 Months Ended				3 Months Ended
	Oct. 31, 2021USD ($)unitcontractrelatedParty	Aug. 31, 2021	Mar. 31, 2021USD ($)unit	Sep. 30, 2017	Mar. 31, 2022USD ($)	Mar. 31, 2021USD ($)unit	Feb. 28, 2019unit	Oct. 31, 2018
Lessor, Lease, Description [Line Items]
Gain on termination of operating lease					$ 0	$ (11)
Number of contracts | contract	2
Number of manufacturing properties | contract	2
Total lease payments receivable					$ 1,461
Proceeds from deposits from customers	$ 127
Sublease, Lease Term 1
Lessor, Lease, Description [Line Items]
Total lease payments receivable	97
Sublease, Lease Term 2
Lessor, Lease, Description [Line Items]
Total lease payments receivable	$ 109
MediaWorks Corporate Headquarters | Additional Space
Lessor, Lease, Description [Line Items]
Operating lease rent-free period		18 months
Operating lease contract term		9 years 11 months
Manufacturing Space in Enfield, United Kingdom
Lessor, Lease, Description [Line Items]
Gain on termination of operating lease			$ 100
Lease termination fee expense			$ 200
Manufacturing Space in Enfield, United Kingdom | Building
Lessor, Lease, Description [Line Items]
Operating lease contract term							15 years
Number of units | unit							3
Number of units surrendered | unit			1			1
Number of contracts | unit	2
Operating lease, number of third parties | relatedParty	2
Office Space in Rockville, Maryland | Building
Lessor, Lease, Description [Line Items]
Operating lease contract term								5 years
Manufacturing Suite in Stevenage, United Kingdom | Manufacturing Facility
Lessor, Lease, Description [Line Items]
Operating lease rent-free period				6 months

Leases - Lease Cost (Details)

Leases - Lease Cost (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Lessor, Lease, Description [Line Items]
Total lease costs	$ 1,430	$ 2,254
Operating cash outflows from operating leases (in thousands)	1,619	1,034
Right-of-use assets obtained in exchange for new operating lease liabilities (in thousands)	$ 0	$ (39,081)
Weighted-average remaining lease term - operating leases (in years)	5 years 6 months	5 years 9 months 18 days
Weighted-average discount rate — operating leases (percent)	7.15%	6.70%
Research and development
Lessor, Lease, Description [Line Items]
Operating lease costs	$ 987	$ 1,572
Variable costs	119	317
Short term lease costs	27	41
General and administrative
Lessor, Lease, Description [Line Items]
Operating lease costs	272	60
Variable costs	15	250
Short term lease costs	$ 10	$ 14

Leases - Schedule of Maturity P

Leases - Schedule of Maturity Payments (Details) $ in Thousands	Mar. 31, 2022USD ($)
Leases [Abstract]
2022	$ 4,050
2023	4,804
2024	4,141
2025	2,903
2026	2,671
Thereafter	4,647
Total lease payments	23,216
Less: imputed interest	(3,961)
Present value of lease liabilities	$ 19,255

Leases - Sublease Classificatio

Leases - Sublease Classification (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Lessor, Lease, Description [Line Items]
Total sublease rental income	$ 65	$ 0
Other income, net
Lessor, Lease, Description [Line Items]
Total sublease rental income	$ 65	$ 0

Leases - Sublease Income Maturi

Leases - Sublease Income Maturity (Details) $ in Thousands	Mar. 31, 2022USD ($)
Leases [Abstract]
2022	$ 203
2023	270
2024	270
2025	270
2026	211
Thereafter	237
Total lease payments receivable	$ 1,461

Commitments and Contingencies -

Commitments and Contingencies - Narrative (Details) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Loss contingency accrual	$ 0	$ 0

Employee Benefit Plans and Se_2

Employee Benefit Plans and Severance Plan (Details) $ in Millions	1 Months Ended
	Jan. 31, 2021USD ($)
Retirement Benefits [Abstract]
Severance costs	$ 1.2

Related parties (Details)

Related parties (Details) $ / shares in Units, $ in Millions	3 Months Ended
	Mar. 31, 2022USD ($)	Nov. 06, 2021contract$ / shares	Feb. 28, 2021shares	Feb. 12, 2021$ / shares
Related Party Transaction
Number of directors | contract		1
Ordinary Shares
Related Party Transaction
Per share price of issuance (usd per share) | $ / shares		$ 5.56
Ordinary Shares | Underwriters public offering
Related Party Transaction
Per share price of issuance (usd per share) | $ / shares				$ 7
Syncona LLP
Related Party Transaction
Purchased ADSs | shares			3,571,428
Autolus | Investee Of Syncona Portfolio Limited | License [Member]
Related Party Transaction
Ownership percentage by noncontrolling owners	10.00%
Blackstone
Related Party Transaction
Contract with customer, liability | $	$ 48.8
Accrued interest | $	$ 2.9
Blackstone | Autolus
Related Party Transaction
Ownership percentage by noncontrolling owners		10.00%